Trial Condition(s):

Seborrheic Dermatitis on the Face

A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

Bayer Identifier:

1401201

ClinicalTrials.gov Identifier:

NCT00408330

EudraCT Number:

2006-002060-26

Study Completed

Trial Purpose

This study is to determine whether a medication on the market for other indications is effective and safe in treating seborrheic dermatitis of the face.

Inclusion Criteria
- Stable or exacerbating seborrheic dermatitis in the facial area
Exclusion Criteria
- Psoriasis
- Atopic dermatitis
- Facial acne and rosacea
- Dermatophytic skin infections
- Parkinson's disease
- Known immunosuppression; HIV infection
- Any condition requiring continuous systemic or topical corticosteroid or antimycotic therapy
- Continuous asthma inhalation treatment requiring > 800 mg corticosteroids
- Any severe disease likely to interfere with the conduct or the planned termination of the study

Trial Summary

Enrollment Goal
48
Trial Dates
black-arrow
Phase
2
Could I receive a placebo?
No
Products
Finacea (Azelaic Acid, BAY39-6251)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

SCIderm Scientific Research

Hamburg, Germany, 20354

Status
Completed
 
Locations

Private Practice

Buchholz, Germany, 21244

Status
Completed
 
Locations

Private Practice

Blankenfelde-Mahlow, Germany, 15831

Status
Completed
 
Locations

Private Practice

Hamburg, Germany, 22049

Status
Completed
 

Trial Design